Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized trial of ARX788 versus physicians choice of treatment in second line HER2-positive gastric cancer and HER2-positive cancer at the gastroesophageal junction.

Next Previous
X
Search
Trial Profile

A randomized trial of ARX788 versus physicians choice of treatment in second line HER2-positive gastric cancer and HER2-positive cancer at the gastroesophageal junction.

Status: Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 16 Dec 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ARX 788 (Primary)
  • Indications Gastric cancer; Oesophageal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ACE-Gastric-02
  • Sponsors Ambrx; NovoCodex Biopharmaceuticals

    • Most Recent Events

    • 09 Dec 2022 According to an Ambrx media release, data from this study is expected in 2023.
    • 04 Oct 2021 Status changed from planning to recruiting, according to an Ambrx media release.
    • 04 Oct 2021 According to an Ambrx media release, first patient has been dosed in this trial in August 2021.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top